KEZAR LIFE SCIENCES INC
1 day chart
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's product portfolio includes KZR-616 and KZR-261. The KZR-616 is a selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib trial in patients with systemic lupus erythematosus (SLE). KZR-261 is being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. The Company has two drug development programs that harness different master regulators of cellular function, which include the immunoproteasome and the Sec61 translocon. The Company’s principal operations are in South San Francisco, California.
Buy US stocks in Australia with $0 brokerage and trade KZR today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.